Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by GRAMPS1996on Jul 31, 2017 10:34am
121 Views
Post# 26528359

Bladder cancer statistics

Bladder cancer statistics

Bladder cancer statistics

Bladder cancer is the ninth most common cancer in the world, with 430,000 new cases diagnosed in 2012

  • Men are more than four times more likely to get bladder cancer than women.
  • Smoking is a major cause of bladder cancer.
  • Infection with schistosomiasis following exposure to infested water is a cause of this cancer, particularly in Africa and the Middle East.
  • Exposure to industrial chemicals such as metalworking fluids is another cause of bladder cancer.
  • Our analysis of worldwide research on the link between diet, weight, physical activity and bladder cancer found strong evidence that drinking water containing arsenic increases the risk of bladder cancer.

Countries with highest rates of bladder cancer

The top 20 countries with the highest incidence of bladder cancer in 2012 are listed in the tables below.

Both sexes

  • Belgium has the highest rate of bladder cancer, followed by Lebanon and Malta.
  • About 59 per cent of bladder cancer cases occur in more developed countries.
  • The highest incidence of bladder cancer is in Northern America and Europe; and the lowest incidence is in Asia, Latin America and the Caribbean.
Rank Country Age-Standardised Rate per 100,000 (World)
1 Belgium 17.5
2 Lebanon 16.6
3 Malta 15.8
4 Turkey 15.2
5 Denmark 14.4
6 Hungary 14.1
7 Spain 13.9
8 Norway 13.5
9 Germany 13.4
10 Egypt 13.1
11 Israel 12.6
12 Armenia 12.3
13 Switzerland 12.2
14 Portugal 12.0
15 Italy 11.8
16= Cyprus 11.6
16= United States of America 11.6
18= Canada 11.5
18= Czech Republic 11.5
18= Iceland 11.5
18= FYR Macedonia 11.5

Source: Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2014. Available from: https://globocan.iarc.fr, accessed on 08/09/2015.

Men

  • Belgium has the highest rate of bladder cancer, followed by Lebanon and Turkey.
  • About 59 per cent of bladder cancer cases occur in more developed countries.
  • The highest incidence of bladder cancer was is in Northern America and Europe; and the lowest incidence is in Asia, Latin America and the Caribbean.
Rank Country Age-Standardised Rate per 100,000 (World)
1 Belgium 31.0
2 Lebanon 29.1
3 Turkey 28.7
4 Armenia 27.3
5 Malta 26.9
6 Spain 26.0
7 Hungary 23.5
8 Denmark 22.9
9 Israel 22.7
9 Germany 22.7
11 Portugal 22.4
12 Cyprus 22.3
13 Egypt 21.8
14= FYR Macedonia 21.6
14= Norway 21.6
16 Italy 21.2
17 Switzerland 20.3
18 Poland 20.2
19 Iraq 19.9
20 United States of America 19.6

Source: Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2014. Available from: https://globocan.iarc.fr, accessed on 08/09/2015.

Women

  • Hungary has the highest rate of bladder cancer, followed by Denmark and Norway.
  • About 58 per cent of bladder cancer cases occur in more developed countries.
  • The highest incidence of bladder cancer was is in Northern America and Europe; and the lowest incidence is in Asia, Latin America and the Caribbean.
Rank Country Age-Standardised Rate per 100,000 (World)
1 Hungary 7.4
2 Denmark 7.0
3 Norway 6.4
4= Belgium 6.2
4= Malta 6.2
6 Lebanon 6.1
7= Mali 6.0
7= Iceland 6.0
9 Malawi 5.9
10= Canada 5.6
10= Czech Republic 5.6
10= Egypt 5.6
13= Switzerland 5.5
13= Germany 5.5
15 Croatia 5.3
16 Iraq 5.2
17= United States of America 5.1
17= Austria 5.1
19= Albania 5.0
19= Ireland 5.0

Source: Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2014. Available from: https://globocan.iarc.fr, accessed on 08/09/2015.


Bullboard Posts